CNBC's Meg Tirrell reports on the Clinton Campaign's plan to combat high drug prices.
Mylan shares were hit again after Senator Amy Klobuchar released a report saying Mylan may have misclassified EpiPen under Medicaid. Senator Klobuchar explains.
CNBC's Meg Tirrell reports the latest on Hillary Clinton's plan to curb drug price hikes and how the pharma industry could react.
Scott Stringer, (D) NYC Comptroller, discusses the city's letter to the board of Mylan over the risks of EpiPen price hikes for New York City's pension funds.
The Democratic presidential candidate would create a consumer response team to monitor drug price hikes.
CNBC's John Harwood reports Hillary Clinton's new plan to tackle drug price hikes.
Fred Hassan, Warburg Pincus Partner & Managing Director, discusses the issue of drug pricing for consumers in the wake of the Mylan EpiPen pricing saga.
CNBC's Meg Tirrell speaks to former Teva CEO Jeremy Levin about drug-price hikes, and why he thinks the pharmaceutical system is in need of change.
Dr. Ezekiel Emanuel, University of Pennsylvania Chair of Medical Ethics & Health Policy, weighs in on the drug pricing debate in the wake of Mylan's EpiPen pricing saga.
CNBC's Meg Tirrell reports the latest on Mylan following the announcement that it will release a generic version of its EpiPen.
Chief pharmacy officer at the Cleveland Clinic discusses Mylan's "generic" version of its own product, the Epipen, on CNBC's "Closing Bell."
Brian Stutland, Equity Armor Investments CIO, shares his bullish take on the health care sector, amid all the political rhetoric surrounding Mylan. The "Fast Money" traders weigh in.
CNBC's Meg Tirrell reports on Mylan's decision to create a "generic" of its own product, the Epipen.
Former FDA Deputy Commissioner Dr. Scott Gottlieb, who's with the American Enterprise Institute, discusses what's wrong with the US health care system.
Steve Brill, lawyer and author of "America's Bitter Pill: Money, Politics, Backroom Deals and the Fight to Fix our Broken Healthcare System" discusses what can be done to make things right with America's health care system.
CNBC's Meg Tirrell reports on Mylan's decision to launch a generic EpiPen as a way of cutting the cost of the treatment.
Amid Mylan launching an EpiPen generic alternative, the “Fast Money Halftime Report” traders and CNBC’s Jim Cramer share their take on Mylan and the biotech sector.
Mylan, Herbalife and T-Mobile are making headlines this Monday morning.
The pharmaceutical company will offer patients a two-pack carton at half price of the branded version.
Dr. Josh Sharfstein, Johns Hopkins University and Former FDA official, discusses the role of the FDA in drug pricing and competition in the pharmaceutical space.